No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
HCWB HCW Biologics
- 0.601
- -0.019-3.06%
Close Jul 22 16:00 ET
- 0.603
- +0.002+0.30%
Post 16:08 ET
22.73MMarket Cap-790P/E (TTM)
0.655High0.600Low12.59KVolume0.655Open0.620Pre Close7.66KTurnover0.07%Turnover RatioLossP/E (Static)37.82MShares2.19052wk High2.60P/B10.73MFloat Cap0.55052wk Low--Dividend TTM17.85MShs Float7.775Historical High--Div YieldTTM8.87%Amplitude0.550Historical Low0.608Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | HCW Biologics Inc : Maxim Group Cuts Target Price to $3 From $4
Express News | HCW Biologics: Settlement Agreement to Resolve Previously Disclosed Arbitration Before Jams Brought by Altor and Nantcell
Express News | HCW Biologics: Under Terms of Settlement, No Party Will Make Monetary Payments to Any Other Party or Person
Express News | HCW Biologics: Entered Confidential Settlement Agreement and Release With Altor Bioscience and Immunitybio
HCW Biologics: A Promising Buy Rating Based on Clinical Advancements and Strategic Growth Opportunities
HCW Biologics | 10-Q: Quarterly report
Comments
The recent and long-term insider transactions suggest a bullish sentiment among insiders towards HCW Biologics, despite the company making losses. The high insider ownership indicates that the company is likely run in the interest of all shareholders.
Chief Financial Officer of HCW Biologics Rebecca Byam Buys 122% More Shares
$HCW Biologics(HCWB.US$Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
3
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg